Clinical Trials Logo

Clinical Trial Summary

This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD) and to assess change in liver fat (expansion cohort only).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04857606
Study type Interventional
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date May 24, 2021
Completion date August 22, 2022

See also
  Status Clinical Trial Phase
Suspended NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Active, not recruiting NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4
Completed NCT01257685 - Selenoprotein P and Non-alcoholic Fatty Liver Disease
Completed NCT00714129 - De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease N/A
Completed NCT00230087 - Iron Depletion Therapy for Type 2 DM and NAFLD Phase 2
Completed NCT00230113 - Effect of Omega-3 PUFA Supplementation in NAFLD Patients Phase 2
Withdrawn NCT02973295 - Silymarin in NAFLD Phase 4
Recruiting NCT04501042 - Investigation on the Role of Gut-liver Axis for Non-alcoholic Steatohepatitis Through Bariatric Surgery
Recruiting NCT04101162 - NAFLD Study: US vs Liver Biopsy N/A
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A